respiratori
tract
infect
rti
lead
caus
death
lowincom
countri
second
lead
caus
death
children
less
year
old
worldwid
accord
world
health
organ
upper
lower
rti
urti
lrti
viral
although
mani
case
pathogen
never
identifi
advanc
viral
diagnost
molecular
virolog
allow
identif
previous
unknown
pathogen
human
metapneumoviru
hmpv
discov
routin
viral
cultur
respiratori
specimen
children
rti
hmpv
implic
common
caus
urti
lrti
children
adult
caus
sever
diseas
immunocompromis
host
hmpv
phylogen
classif
illustr
method
discoveri
van
den
hoogen
colleagu
identifi
viral
isol
cultur
nasal
secret
patient
present
symptom
rti
isol
caus
cytopath
effect
tertiari
monkey
kidney
cell
morpholog
indistinguish
though
later
respiratori
syncyti
viru
rsv
electron
microscopi
investig
observ
pleomorph
particl
measur
nm
short
envelop
project
rare
nucleocapsid
featur
characterist
paramyxovirida
repres
electron
micrograph
hmpv
shown
fig
result
also
consist
inclus
new
viru
paramyxovirida
includ
abrog
infect
chloroform
treatment
lack
hemagglutin
turkey
chicken
guinea
pig
erythrocyt
depend
trypsin
replic
cell
cultur
member
paramyxovirida
famili
envelop
virus
singlestrand
nonseg
neg
sens
rna
paramyxovirida
includ
subfamili
paramyxovirina
pneumovirina
pneumovirina
subfamili
divid
genera
pneumoviru
metapneumoviru
rsv
import
human
pathogen
pneumoviru
genu
metapneumovirus
differ
pneumovirus
absenc
nonstructur
protein
differ
gene
order
sequenc
data
hmpv
demonstr
absenc
open
read
frame
orf
posit
f
gene
adjac
gene
confirm
classif
metapneumoviru
genom
organ
hmpv
orf
code
protein
known
member
metapneumoviru
genu
avian
pneumoviru
sequenc
hmpv
rna
suggest
hmpv
make
protein
three
viral
glycoprotein
attach
g
fusion
f
small
hydrophob
sh
believ
insert
lipid
envelop
f
protein
contain
cleavag
site
hydrophob
region
heptad
repeat
extracellular
domain
featur
distinct
viral
protein
fuse
viral
host
cell
membran
g
protein
heavili
glycosyl
type
ii
mucinlik
protein
glycosyl
pattern
effici
export
host
cell
surfac
type
ii
membran
orient
suggest
role
attach
protein
sequenc
g
protein
highli
variabl
strain
similar
rsv
g
protein
suggest
serotyp
variat
protein
discuss
later
gprotein
defici
mutant
abl
replic
vivo
vitro
albeit
less
effici
wildtyp
hmpv
suggest
gprotein
absolut
requir
viral
replic
function
sh
protein
remain
unknown
helic
nucleocapsid
believ
compos
viral
rna
nucleocapsid
protein
n
phosphoprotein
protein
p
larg
polymeras
protein
l
transcript
enhanc
protein
nucleocapsid
protein
n
p
l
like
involv
viral
replic
transcript
protein
pneumovirina
regulatori
protein
function
transcript
elong
factor
promot
viral
assembl
rsv
hmpv
strain
lack
frequent
point
mutat
display
upregul
transcript
support
role
regul
viral
transcript
matrix
protein
surround
nucleocapsid
within
lipid
envelop
like
facilit
connect
nucleocapsid
viral
lipid
envelop
van
den
hoogen
separ
hmpv
lineag
base
sequenc
homolog
distinct
lineag
call
hmpv
type
b
identifi
multipl
phylogen
studi
type
group
subtyp
call
overal
genet
ident
type
wherea
amino
acid
sequenc
ident
hmpv
type
b
group
concord
base
sequenc
divers
gene
encod
n
f
g
l
protein
although
extent
sequenc
divers
vari
subtyp
distinguish
divers
gene
sequenc
surfac
glycoprotein
g
f
ident
f
gene
subtyp
within
group
b
wherea
ident
g
gene
sequenc
epidemiolog
human
known
natur
host
hmpv
viru
presum
spread
person
person
respiratori
droplet
similar
paramyxovirus
although
definit
determin
hmpv
infect
detect
worldwid
report
north
south
america
europ
asia
africa
australia
serolog
studi
store
specimen
indic
hmpv
infect
human
least
decad
hmpv
infect
season
winter
epidem
occur
decemb
april
northern
hemispher
simultan
slightli
later
rsv
epidem
fig
subtyp
hmpv
usual
circul
season
predomin
serotyp
may
altern
consecut
year
locat
wherea
agapov
colleagu
found
shift
predomin
isol
type
b
type
st
loui
missouri
usa
mackay
colleagu
detect
shift
predomin
subtyp
isol
queensland
australia
sequenti
year
hmpv
commonli
diseas
young
children
caus
approxim
lrti
infant
studi
second
lead
caus
bronchiol
rsv
multipl
method
evalu
seropreval
shown
children
evid
prior
hmpv
infect
age
year
peak
age
hmpv
infect
rang
month
typic
older
rsv
younger
influenza
even
distribut
among
age
group
studi
potenti
risk
factor
viral
infect
hmpv
coronaviru
show
stronger
associ
childcar
attend
rsv
picornavirus
influenza
virus
adenoviru
parainfluenza
virus
young
healthi
adult
higher
yearli
hmpv
infect
rate
rang
elderli
highrisk
adult
perhap
frequent
contact
children
yearli
seroconvers
rate
patient
year
old
live
longterm
care
facil
ltcf
hmpv
outbreak
among
elderli
patient
ltcf
mortal
confirm
case
hmpv
seropreval
found
among
adult
underli
chronic
obstruct
pulmonari
diseas
copd
hmpv
respiratori
pathogen
known
caus
lrti
urti
detect
rare
asymptomat
host
hmpv
implic
caus
childhood
bronchiol
pneumonia
asthma
exacerb
croup
also
play
role
exacerb
copd
adult
sever
diseas
immunocompromis
host
hmpv
isol
respiratori
specimen
children
adult
pneumonia
william
colleagu
retrospect
identifi
hmpv
frozen
respiratori
sampl
collect
year
children
lrti
sampl
previous
test
neg
virus
hmpv
rate
sampl
previous
found
posit
anoth
viru
coinfect
rate
demonstr
hmpv
often
found
sole
pathogen
diagnos
cohort
includ
bronchiol
croup
pneumonia
asthma
exacerb
children
present
hmpv
lrti
commonli
preced
urti
fever
dyspnea
cough
coryza
sign
hmpv
infect
includ
rhiniti
wheezingstridor
tachypnea
abnorm
tympan
membran
pharyng
rhonchi
rale
hypoxia
less
analysi
patient
present
acut
wheez
hmpv
account
case
pathogen
detect
chest
radiograph
cxr
patient
hmpv
lrti
abnorm
half
patient
find
includ
diffus
perihilar
infiltr
peribronchi
cuf
lobar
infiltr
hyperaer
fig
white
blood
cell
count
creactiv
protein
level
typic
normal
acut
hmpv
infect
rang
l
mean
mgl
respect
clear
whether
sever
hmpv
lrti
differ
respiratori
virus
william
colleagu
found
differ
rate
abnorm
cxr
hospit
emerg
room
visit
compar
sever
diseas
caus
hmpv
respiratori
virus
influenza
rsv
parainfluenza
adenoviru
smaller
studi
thailand
found
longer
mean
hospit
vs
day
children
hmpv
compar
rsv
lrti
although
studi
show
differ
rate
outpati
treatment
inpati
intens
care
unit
icu
admiss
hmpv
rsv
william
colleagu
report
clinic
differ
infect
caus
hmpv
type
b
howev
vicent
colleagu
suggest
infect
hmpv
type
sever
infect
type
b
found
children
type
like
present
pneumonia
higher
mean
sever
score
base
oxygen
satur
less
admiss
hospit
icu
earli
studi
suggest
coinfect
hmpv
frequent
occur
sever
rsv
bronchiol
children
greensil
colleagu
studi
cohort
infant
rsvposit
bronchiol
admit
icu
found
overal
without
underli
condit
test
posit
hmpv
investig
follow
observ
larger
retrospect
studi
children
less
year
old
bronchiti
found
infant
coinfect
hmpv
rsv
significantli
like
admit
icu
infant
infect
rsv
william
colleagu
later
report
epidemiolog
clinic
differ
children
infect
hmpv
children
hmpv
coinfect
anoth
respiratori
viru
addit
studi
van
woensel
colleagu
find
hmpv
coninfect
children
requir
mechan
ventil
rsv
lrti
taken
togeth
studi
suggest
hmpv
coinfect
requir
particularli
common
sever
manifest
rsv
bronchiol
young
children
william
colleagu
describ
children
hmpv
urti
period
specimen
neg
respiratori
virus
test
posit
hmpv
symptom
sign
frequent
includ
fever
coryza
cough
rhiniti
pharyng
otalgia
abnorm
tympan
membran
sign
occur
less
patient
hoars
conjunct
hmpv
common
pathogen
isol
anoth
cohort
children
test
pertussi
hmpv
versu
test
posit
bordetella
pertussi
suggest
overlap
sign
symptom
whoop
cough
lrti
hmpv
serotyp
seem
affect
urti
diseas
sever
presenc
otalgia
abnorm
tympan
membran
suggest
hmpv
associ
acut
otiti
media
children
prospect
cohort
children
age
year
present
acut
otiti
media
infect
hmpv
hmpv
signific
contributor
urti
adult
account
urti
healthi
adult
adult
cardiopulmonari
diseas
hmpv
also
implic
copd
exacerb
detect
patient
copd
exacerb
anoth
studi
document
patient
copd
exacerb
seroconvert
hmpv
immunocompromis
vulner
host
hmpv
caus
urti
lrti
individu
infect
human
immunodefici
viru
hiv
south
africa
hospit
rate
hmpv
pneumonia
greater
children
infect
hiv
children
hiv
neg
separ
studi
howev
investig
found
signific
clinic
differ
hivneg
hivposit
children
hospit
hmpv
infect
though
hivinfect
children
trend
toward
longer
hospit
vs
day
clinic
featur
hmpv
infect
hivposit
cohort
includ
mean
satur
room
air
children
requir
supplement
oxygen
half
subject
wheez
rale
receiv
diagnosi
bronchiol
diagnosi
pneumonia
hmpv
caus
sever
respiratori
diseas
immunocompromis
host
demonstr
numer
case
report
sever
hmpv
infect
report
patient
acut
lymphoblast
leukemia
lymphoma
lung
cancer
patient
follow
lung
transplant
hematopoet
stem
cell
transplant
hsct
without
concurr
neutropenia
hmpv
identifi
autopsi
caus
pneumoniarel
death
child
treat
hmpvinfect
children
younger
year
old
chemotherapi
die
acquir
respiratori
distress
syndrom
adult
older
year
old
leukemia
neutropenia
hmpv
die
pneumon
prospect
studi
adult
hsct
recipi
lrti
urti
sampl
pathogen
isol
test
posit
hmpv
yearli
infect
rate
patient
five
patient
lrti
significantli
patient
lrti
allogen
transplant
patient
die
separ
seri
hsct
transplant
patient
test
posit
hmpv
progress
hemorrhag
pneumonia
respiratori
failur
septic
shock
patient
die
symptomat
patient
lung
transplant
bronchoalveolar
lavag
bal
sampl
test
posit
hmpv
patient
clinic
recov
although
seri
lung
transplant
patient
infect
hmpv
develop
graft
dysfunct
similar
rsv
highrisk
condit
prematur
birth
congenit
heart
diseas
chronic
lung
diseas
increas
sever
diseas
likelihood
hospit
hmpv
infect
sever
cohort
hmpvinfect
children
includ
underli
condit
prematur
chronic
lung
diseas
congenit
heart
diseas
prospect
studi
follow
infant
prematur
congenit
heart
diseas
found
although
rti
caus
hmpv
infect
led
moder
sever
diseas
ill
result
posit
viral
diagnosi
suggest
underdiagnosi
pathogen
studi
anim
model
use
studi
pathophysiolog
immunogen
hmpv
infect
includ
cotton
rat
balbc
mous
cynomolgu
macaqu
intranas
challeng
balbc
mice
cotton
rat
hmpv
result
peak
viral
titer
nasal
turbin
day
lung
homogen
day
post
infect
small
anim
model
show
viral
clearanc
respiratori
tract
day
although
balbc
mice
prolong
infect
biphas
viral
replic
hmpv
serotyp
b
although
mice
show
weight
loss
breath
problem
day
post
infect
rat
seem
asymptomat
macaqu
viral
load
respiratori
secret
peak
day
decreas
zero
day
post
infect
macaqu
display
rhinorrhea
nasal
inocul
hmpv
rodent
nonhuman
primat
hmpv
detect
throughout
respiratori
tract
spread
intern
organ
histopatholog
chang
lung
hmpv
infect
studi
rodent
nonhuman
primat
human
peak
infect
hmpv
rat
lung
show
peribronchi
lymphoplasmocyt
infiltr
edema
bronchial
submucosa
small
medium
bronchi
show
hypersecretori
epithelium
mononuclear
infiltr
caus
alveolar
interstiti
expans
bronchial
lumen
contain
slough
epithelium
neutrophil
macrophag
debri
balbc
mice
develop
parenchym
pneumonia
neutrophil
infiltr
hmpv
infect
seem
less
sever
peribronchiol
cotton
rat
although
increas
histopatholog
score
persist
day
compar
week
rat
macaqu
histopatholog
studi
show
similar
loss
ciliat
epithelium
neutrophil
transmigr
interstiti
edema
intralumin
slough
epitheli
cell
debri
six
bal
sampl
lung
biopsi
children
hmpv
infect
obtain
month
month
posit
hmpv
specimen
report
bal
sampl
show
epitheli
cell
degener
necrosi
ciliocytophthoria
round
red
cytoplasm
inclus
hemosiderinladen
macrophag
frequent
neutrophil
mucu
fig
acut
diseas
lung
biopsi
show
eosinophil
nuclear
cytoplasm
inclus
fig
longstand
diseas
chronic
airway
inflamm
intraalveolar
foami
hemosiderinladen
macrophag
observ
immunohistochemistri
provid
insight
locat
extent
viral
replic
respiratori
tract
cotton
rat
macaqu
hmpv
antigen
detect
lumin
surfac
epitheli
cell
nasal
tissu
bronchiol
macaqu
individu
group
ciliat
cell
affect
often
morpholog
normal
tissu
goblet
basal
cell
spare
occasion
posit
hmpv
stain
identifi
alveoli
includ
type
pneumocyt
adjac
alveolar
macrophag
intralumin
debri
although
giant
cell
spare
unclear
whether
hmpv
intralumin
macrophag
infect
macrophag
phagocytosi
infect
materi
hmpv
infect
respiratori
tract
lead
increas
level
chemokin
cytokin
respiratori
secret
anim
human
level
macrophag
inflammatori
protein
regul
activ
normal
cell
express
secret
rant
interferon
g
ifng
interleukin
monocyt
chemotact
protein
increas
lung
hmpvinfect
mice
level
mrna
cytokin
lung
except
measur
also
increas
hmpv
infect
cotton
rat
kinet
level
protein
increas
decreas
parallel
kinet
inflammatori
respons
within
rodent
lung
decreas
baselin
level
day
infect
analysi
respiratori
specimen
infant
hmpv
rsv
infect
similar
clinic
sever
hmpv
elicit
lower
product
tnfa
investig
suggest
mechan
innat
immun
must
elicit
human
hmpv
infect
account
clinic
sever
mechan
might
includ
direct
epitheli
damag
polar
lead
pulmonari
airway
hyperreact
chemokinemedi
inflamm
evid
polar
hmpv
infect
includ
significantli
lower
ratio
secret
infant
infect
hmpv
compar
influenza
rsv
suggest
bia
thelper
cell
respons
pathogen
investig
also
report
compar
influenza
hmpv
rsv
infect
result
lower
level
ifng
level
cytokin
product
relat
sever
ill
virus
studi
suggest
despit
structur
clinic
sequela
similar
pathogen
innat
immun
inflammatori
respons
hmpv
uniqu
fulli
understood
discuss
earlier
hmpv
discov
cultur
respiratori
sampl
tertiari
monkey
kidney
cell
cytopath
effect
appear
day
later
typic
caus
rsv
includ
cellular
round
without
syncytia
format
fig
viru
grow
effici
rhesu
monkey
kidney
cell
line
exogen
trypsin
hmpv
grow
poorli
vero
human
lung
adenocarcinoma
cell
line
slowli
mdck
cell
line
recent
shown
hmpv
replic
well
without
trypsin
human
bronchiolar
cell
line
despit
improv
cultur
gener
insensit
detect
hmpv
along
slow
replic
viru
cultur
make
uncommon
method
diagnosi
hmpv
immunofluoresc
stain
shell
vial
centrifug
cultur
svcc
use
success
rapid
detect
respiratori
virus
svcc
allow
detect
viral
antigen
cultur
time
day
monoclon
antibodi
specif
hmpv
use
immunofluoresc
assay
ifa
directli
patient
specimen
use
detect
hmpv
use
svcc
sever
cell
line
subsequ
studi
found
cell
line
sensit
svcc
hmpv
incub
time
day
increas
cultur
sensit
immunoassay
immunofluoresc
stain
hmpv
respiratori
secret
moder
sensit
high
specif
use
antihmpv
mous
monoclon
igg
antibodi
recogn
subgroup
hmpv
b
ebihara
colleagu
compar
ifa
revers
transcriptasepolymeras
chain
reaction
rtpcr
posterior
nasal
sampl
ifa
posit
symptomat
patient
test
posit
hmpv
rtpcr
addit
rtpcr
neg
patient
test
posit
ifa
sensit
specif
ifa
compar
rtpcr
found
respect
similar
result
obtain
direct
fluoresc
antibodi
stain
respiratori
specimen
pool
mab
sensit
specif
given
eas
object
like
clinic
role
enzym
immunoassay
eia
detect
antigen
rapidli
nasopharyng
aspir
commerci
immunoassay
hmpv
produc
biotrin
ltd
mount
merrion
co
dublin
ireland
approv
us
food
drug
administr
fda
clinic
use
combin
mab
matrix
fusion
protein
use
captur
antibodi
use
cultur
rtpcr
gold
standard
eia
found
sensit
specif
respect
high
proport
sampl
gave
equivoc
result
assay
perform
discrep
analysi
investig
count
result
posit
result
care
statist
evalu
test
need
despit
lower
sensit
pcr
eas
rapid
lower
cost
ifa
eia
make
clinic
diagnost
could
feasibl
offer
microbiolog
laboratori
pcr
pcr
found
higher
sensit
cultur
ifa
sensit
specif
rtpcr
techniqu
develop
detect
hmpv
nasopharyng
aspir
bronchoalveolar
lavag
specimen
primer
chosen
amplifi
segment
n
gene
sequenc
shown
sensit
compar
primer
direct
l
p
f
gene
sensit
respect
pcr
amplif
product
subject
enzymelink
amplicon
hybrid
assay
elaha
techniqu
yield
increas
sensit
compar
routin
electrophoresi
realtim
rtpcr
use
primer
use
pcrelaha
increas
sensit
reduc
turnaround
time
risk
contamin
assay
nucleic
acid
sequencebas
amplif
nasba
assay
target
gene
found
slightli
less
sensit
pediatr
patient
compar
rtpcr
n
gene
investig
also
found
rtpcr
nasba
slightli
less
sensit
detect
hmpv
serotyp
b
real
time
rtpcr
hmpv
avail
assay
approv
fda
xtag
respiratori
viral
panel
luminex
austin
tx
usa
multiplex
pcr
assay
sever
respiratori
virus
pcr
product
detect
hybrid
oligonucleotid
fluoresc
bead
analyz
flow
cytometri
report
sensit
specif
respect
hmpv
second
real
time
rtpcr
approv
fda
hmpv
pro
assay
genprob
prodess
waukesha
wi
usa
packag
insert
assay
claim
sensit
specif
enzymelink
immunosorb
assay
elisa
first
develop
use
hmpvinfect
cell
antigen
detect
hmpv
antibodi
sera
increas
sensit
specif
recombin
n
protein
develop
captur
antigen
n
protein
select
antigen
highli
conserv
hmpv
type
b
elisa
use
recombin
na
nb
protein
reliabl
detect
seroconvers
recent
infect
individu
although
signific
crossreact
type
caus
antibodi
recognit
conserv
epitop
elisa
also
develop
use
recombin
f
protein
antigen
also
show
crossreact
hmpv
serotyp
b
develop
recombin
gprotein
hmpv
subgroup
endo
colleagu
abl
detect
subtyp
specif
antibodi
convalesc
sampl
hmpvinfect
children
clinic
present
hmpv
includ
urti
lrti
similar
rsv
differenti
diagnosi
hmpv
includ
respiratori
virus
influenza
b
rsv
parainfluenza
virus
rhinovirus
coronavirus
parainfluenza
virus
addit
bacteri
caus
communityacquir
pneumonia
must
also
consid
patient
underli
asthma
copd
acut
hmpv
infect
may
mimic
exacerb
condit
differenti
diagnosi
hmpv
summar
tabl
current
approv
specif
therapi
hmpv
infect
treatment
support
sever
agent
evalu
effect
hmpv
replic
vitro
anim
model
ribavirin
pool
human
immunoglobulin
inhibit
hmpv
rsv
replic
equal
cell
cultur
ribavarin
also
reduc
level
hmpv
inflamm
infect
balbc
mice
palivizumab
chemotherapeut
direct
f
protein
rsv
activ
hmpv
sulfat
sialyl
lipid
known
inhibit
rsv
replic
cell
cultur
cotton
rat
model
also
shown
inhibit
hmpv
replic
syncytia
format
celltocel
viru
spread
cultur
none
compound
systemat
test
human
treatment
hmpv
infect
although
case
report
describ
appar
success
treatment
ribavirin
patient
undergon
lung
transplant
sever
hmpv
infect
novel
experiment
therapeut
hmpv
evalu
model
system
human
two
potent
small
interf
rna
target
nucleoprotein
phosphoprotein
mrna
inhibit
hmpv
replic
vitro
subnanomolar
concentr
anoth
strategi
therapi
target
coiledcoil
structur
form
multim
fprotein
fusion
viral
hostcel
membran
treatment
hmpvinfect
mice
peptid
mimic
hydrophob
fprotein
heptad
repeat
protect
mice
lethal
hmpv
infect
peptid
given
time
initi
infect
given
day
later
administr
time
hmpv
infect
also
prevent
infect
associ
airway
obstruct
reduc
product
inflammatori
marker
rant
ifng
mous
lung
controversi
whether
hmpv
genet
lineag
b
differ
serotyp
van
den
hoogen
colleagu
studi
vitro
neutral
hmpv
infect
antisera
rais
ferret
infect
type
b
hmpv
found
reduc
neutral
capac
antisera
rais
heterolog
hmpv
lineag
preserv
neutral
hmpv
strain
within
lineag
suggest
lineag
b
repres
distinct
serotyp
howev
skiadopoulo
colleagu
measur
crossprotect
efficaci
type
b
hmpv
hamster
nonhuman
primat
model
found
hmpv
type
b
highli
antigen
relat
confer
signific
crossprotect
measur
viral
replic
respiratori
tract
indic
repres
distinct
serotyp
whether
crossprotect
human
hmpv
type
remain
fulli
explor
human
adult
popul
typic
show
seropreval
stabl
neutral
antibodi
hmpv
reinfect
rate
adult
yearli
thought
frequent
reinfect
throughout
life
explain
ubiquit
presenc
antihmpv
antibodi
adult
popul
high
frequenc
seroposit
children
frequent
infect
seroconvers
adult
suggest
immun
hmpv
short
live
probabl
provid
incomplet
protect
reinfect
hmpv
also
well
document
children
william
colleagu
describ
sever
patient
present
distinct
hmpv
clinic
episod
homolog
heterolog
hmpv
lineag
recurr
infect
children
caus
homolog
heterolog
strain
also
report
consist
report
recurr
infect
human
subsequ
season
cynomolgu
macaqu
infect
consecut
dose
wildtyp
hmpv
protect
challeng
infect
month
find
suggest
vaccin
candid
would
requir
enhanc
immunogen
confer
longterm
protect
